MTDMettler Toledo

$1,668.79+23% 1Y

$1,668.79

$1.0K52 weeks$1.7K

Is the price fair?

Fair

Neither cheap nor expensive: nothing decisive, though priced for +14% a year vs +1% a year delivered.

1 to watch, 1 neutral, 1 without data

What the price assumes~+14% a yearderived · Jun 30, 2026

Priced for ~14% a year FCF growth. The price already bakes in strong, sustained growth.

Vs its own P/E rangemid-range for this companyderived

In its normal range: P/E 37.6 vs a 35.2 median over 41 quarters (+7% vs median).

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)behind 79% of the market

FCF yieldbehind 81% of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

Mettler Toledo trades at 37.6× earnings against 36.7× for the median Diagnostics & Research name, more expensive than its own group.

37.6

Trailing P/E · Diagnostics & Research median 36.7 · 1.02× the median: the market pays up for this one

Price / sales: 8.09
Price / sales · today's price, trailing year to Jun 30, 2026
Free cash flow yield: 2.6%
Free cash flow yield · Diagnostics & Research median 2.9%
Growth the price implies: +14%
Growth the price implies · The price pays for +14% free cash flow growth a year for a decade; the business has delivered +0.22% a year over the last three.

Details›

What the market has paid for these earnings: 41 quarters of its own multiple × $44.38 of trailing earnings per share
Method	Per share
Its own P/E history, lower quartile	$1,359.65
Its own P/E history, median	$1,563.31
Its own P/E history, upper quartile	$1,733.94
52-week range	$1,025.53 – $1,685.48
Today	$1,668.79

Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.